Primary outcome | ≥20% Weakness in ≥1 myotome |
Risk (95% CI)* |
RR (95% CI)† | |
Group | Yes | No | ||
Lidocaine | 25 (41.7) | 35 (58.3) | 41.7 (29.8 to 54.5) | 0.83 (0.56 to 1.23) |
Saline | 30 (50.0) | 30 (50.0) | 50.0 (37.5 to 62.5) | |
Total | 55 (45.8) | 65 (54.2) | 45.8 (37.1 to 54.9) | |
Secondary outcome | ≥50% Pain reduction | |||
Lidocaine | 19 (32.2) | 40 (67.8) | 32.2 (20.3 to 44.1) | 1.53 (0.82 to 2.86) |
Saline | 12 (21.1) | 45 (78.9) | 26.7 (13.8 to 39.6) | |
Total | 31 (26.7) | 85 (73.3) | 26.7 (18.7 to 34.8) |
Values are frequency (%) unless specified otherwise. P value from Pearson's χ2 test.
Patients whose baseline NRS scores were missing or zero were excluded from the analysis.
Patients whose post-NRS scores were missing were considered treatment failure (ie, % change=0% and 50% pain reduction=no).
Patients whose baseline and post-NRS scores were both zero were excluded from the analysis.
*Risk (%) = (freq (yes) / freq (total))×100
†Relative risk=risk (lidocaine) / risk (saline)
freq, frequency; NRS, numerical rating scale; RR, relative risk.